Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
IP

NASDAQ · IPHA

Innate Pharma S.A.

Healthcare · Biotechnology

$1.62

Up+$0.14 (+9.46%)

Updated Oct 11, 2026, 1:08 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
159.21M
P/E ratio
-3.1
Dividend yield
0.00%
52-week range
$1.17 – $2.71
Volume
46.88K
Avg. volume
194.86K

Price performance · IPHA

IPHA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

IPHA closed at $1.62 after 20 trading sessions, down 12.43% for the selected period.

Last close
$1.62
Period change
-12.43%
Period low
$1.48
Period high
$2.01
Daily close
View OHLC price history
IPHA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$1.49$1.68$1.49$1.6246.88K
Oct 8, 2026$1.505$1.54$1.47$1.4818.37K
Oct 7, 2026$1.54$1.55$1.5001$1.5213.82K
Oct 6, 2026$1.58$1.65$1.53$1.59133.73K
Oct 5, 2026$1.545$1.69$1.5325$1.58107.79K
Oct 2, 2026$1.56$1.69$1.53$1.5692.74K
Oct 1, 2026$1.595$1.67$1.58$1.5964.05K
Sep 30, 2026$1.61$1.78$1.61$1.6337.81K
Sep 29, 2026$1.63$1.6653$1.59$1.6031.8K
Sep 28, 2026$1.71$1.79$1.66$1.7042.27K
Sep 25, 2026$1.67$1.70$1.6101$1.7031.02K
Sep 24, 2026$1.7232$1.73$1.69$1.7017.69K
Sep 23, 2026$1.81$1.81$1.76$1.7623.67K
Sep 22, 2026$1.84$1.84$1.77$1.8055.82K
Sep 21, 2026$1.86$1.86$1.79$1.8677.04K
Sep 18, 2026$1.92$1.94$1.8501$1.9091.44K
Sep 17, 2026$1.99$1.99$1.82$1.91193.77K
Sep 16, 2026$1.86$2.20$1.84$2.01210.92K
Sep 15, 2026$1.85$1.92$1.84$1.8647.79K
Sep 14, 2026$1.86$1.90$1.813$1.8520.79K

Latest IPHA news

The latest Smart Investors Daily articles mentioning IPHA.

Stock researchCompany · Overview

IPHA research

Overview

Company profile and research snapshot.

Company profile

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.50
Implied upside
—
Analysts
9
IPHA recent ratings
DateFirmRatingTarget
Sep 21, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Sep 17, 2026ODDO BHFBuy—
Sep 17, 2026PORTZAMPARC BNP PARIBASBuy—
Jun 23, 2026ODDO BHFBuy—
Jun 22, 2026ODDO BHFBuy—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Dec 11, 2025

Innate Pharma Releases Its 2026 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By